BeOne Medicines (ONC) Stock Forecast, Price Target & Predictions
ONC Stock Forecast
BeOne Medicines (ONC) stock forecast, based on 15 Wall Street analysts, predicts a 12-month average price target of $426.50, with a high of $470.00 and a low of $370.00. This represents a 5.67% increase from the last price of $403.60.
ONC Stock Rating
BeOne Medicines stock's rating consensus is Buy, based on 15 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 15 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).
Buy
ONC Price Target Upside V Benchmarks
| Type | Name | Upside |
|---|---|---|
| Stock | BeOne Medicines | 5.67% |
| Sector | Healthcare Stocks | 15.45% |
| Industry | Biotech Stocks | 41.48% |
Price Target Trends
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 1 | 5 | 24 |
| Avg Price Target | $470.00 | $437.80 | $409.67 |
| Last Closing Price | $403.60 | $403.60 | $403.60 |
| Upside/Downside | 16.45% | 8.47% | 1.50% |
Ratings Trends
| Date | Strong Buy | Buy | Hold | Sell | Strong Sell | Total |
|---|---|---|---|---|---|---|
| Nov, 26 | 7 | 19 | 1 | - | - | 27 |
| Oct, 26 | 7 | 20 | 1 | - | - | 28 |
| Sep, 26 | 7 | 20 | 1 | - | - | 28 |
| Aug, 26 | 8 | 20 | - | - | - | 28 |
| Jul, 26 | 8 | 19 | 1 | - | - | 28 |
Analyst Price Target Forecasts
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2026 | Faisal Khurshid | Jefferies | $470.00 | $391.28 | 20.12% | 16.45% |
| Oct 16, 2026 | Sean Laaman | Morgan Stanley | $425.00 | $368.08 | 15.46% | 5.30% |
| Oct 08, 2026 | RBC Capital | $459.00 | $341.10 | 34.56% | 13.73% | |
| Oct 07, 2026 | Gregory Renza | Truist Financial | $420.00 | $365.21 | 15.00% | 4.06% |
| Sep 10, 2026 | Barclays | $415.00 | $351.00 | 18.23% | 2.82% | |
| Aug 10, 2026 | Kalpit Patel | Wolfe Research | $370.00 | $358.38 | 3.24% | -8.33% |
| Aug 06, 2026 | Barclays | $407.00 | $327.53 | 24.26% | 0.84% | |
| Jul 14, 2026 | Barclays | $403.00 | $303.96 | 32.58% | -0.15% | |
| Jul 13, 2026 | Jefferies | $380.00 | $298.70 | 27.22% | -5.85% | |
| Jul 07, 2026 | Truist Financial | $416.00 | $308.46 | 34.86% | 3.07% |
Analyst Rating Forecasts
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 05, 2026 | Jefferies | Buy | Buy | hold |
| Oct 16, 2026 | Morgan Stanley | Overweight | Overweight | hold |
| Oct 08, 2026 | RBC Capital | Outperform | Outperform | hold |
| Sep 10, 2026 | Barclays | Overweight | Overweight | hold |
| Aug 10, 2026 | Wolfe Research | Outperform | Outperform | hold |
| Aug 06, 2026 | Morgan Stanley | Overweight | Overweight | hold |
| Aug 06, 2026 | Citigroup | Buy | Buy | hold |
| Aug 06, 2026 | Citigroup | Outperform | Outperform | hold |
| Aug 06, 2026 | Barclays | Overweight | Overweight | hold |
| Jul 13, 2026 | Jefferies | Buy | Positive | upgrade |
Financial Forecast
EPS Forecast
Annual
| Dec 24 | Dec 25 | Dec 26 | |
|---|---|---|---|
| Reported | $-6.12 | $34.19 | - |
| Avg Forecast | $-5.83 | $-0.02 | $5.53 |
| High Forecast | $-5.20 | $2.11 | $8.75 |
| Low Forecast | $-6.62 | $-3.52 | $0.75 |
| Surprise % | 4.97% | -171050.00% | - |
Revenue Forecast
Annual
| Dec 24 | Dec 25 | Dec 26 | |
|---|---|---|---|
| Reported | $3.81B | $5.34B | - |
| Avg Forecast | $3.77B | $4.84B | $5.98B |
| High Forecast | $3.78B | $4.96B | $7.00B |
| Low Forecast | $3.75B | $4.71B | $5.02B |
| Surprise % | 1.07% | 10.39% | - |
Net Income Forecast
Annual
| Dec 24 | Dec 25 | Dec 26 | |
|---|---|---|---|
| Reported | $-644.79M | $286.93M | - |
| Avg Forecast | $-613.83M | $-2.11M | $582.26M |
| High Forecast | $-547.50M | $222.16M | $921.72M |
| Low Forecast | $-697.01M | $-370.61M | $78.97M |
| Surprise % | 5.04% | -13726.08% | - |